Crewe Advisors LLC Takes $50,000 Position in Novo Nordisk A/S (NYSE:NVO)

Crewe Advisors LLC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the first quarter, according to its most recent filing with the SEC. The fund acquired 393 shares of the company’s stock, valued at approximately $50,000.

Other institutional investors have also added to or reduced their stakes in the company. First PREMIER Bank bought a new position in shares of Novo Nordisk A/S in the first quarter worth $25,000. CNB Bank bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $26,000. Dixon Mitchell Investment Counsel Inc. bought a new position in shares of Novo Nordisk A/S in the first quarter worth approximately $26,000. Orion Capital Management LLC purchased a new stake in Novo Nordisk A/S in the first quarter valued at approximately $26,000. Finally, Frank Rimerman Advisors LLC bought a new stake in Novo Nordisk A/S during the fourth quarter valued at approximately $30,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.3 %

Shares of NYSE:NVO traded down $0.35 during midday trading on Friday, hitting $127.51. 1,198,635 shares of the stock traded hands, compared to its average volume of 4,410,833. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $572.20 billion, a PE ratio of 43.70, a P/E/G ratio of 1.32 and a beta of 0.41. Novo Nordisk A/S has a one year low of $77.96 and a one year high of $148.15. The business’s 50 day moving average is $138.79 and its two-hundred day moving average is $128.11.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The firm had revenue of $9.52 billion for the quarter, compared to analysts’ expectations of $9.23 billion. As a group, research analysts forecast that Novo Nordisk A/S will post 3.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on NVO shares. The Goldman Sachs Group assumed coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target on the stock. BMO Capital Markets reaffirmed an “outperform” rating and issued a $163.00 target price on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. Argus lifted their price target on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Monday, July 1st. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $145.67.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.